Status: Not yet recruiting
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects with Symptomatic Early Hip Osteoarthritis. TG-C will be administered to the target hip by a single ultrasound (or fluoroscopy)-guided, intra-articular injection with image capture showing correct injection of study drug into the femoroacetabular joint. Patients will be followed for 12 months for safety and efficacy.
Participants needed: 255
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Kolon TissueGene, Inc.Updated: May 22, 2026
Eligibility criteria
Aged 18 to 80 years old [+8]
The subject exhibits severe symptoms in the target hip that result in difficulty... [+23]